GLP-1 Side Effect Management Decision Tree: Clinical Algorithms for Providers
Evidence-based clinical decision algorithms for managing common GLP-1 side effects including nausea, vomiting, constipation, diarrhea, and injection site reactions.
More on Provider-Facing
Clinical Decision Guide
Stepwise management algorithms for common GLP-1 adverse events. Severity-graded approach: supportive care first, dose modification second, discontinuation last resort. Evidence-based strategies to maximize adherence and minimize discontinuation.
Side Effect Management Algorithms
Nausea
Mild
Dietary modification: small meals, bland foods, ginger. Continue current dose.
Moderate
Add ondansetron 4mg PRN. Slower eating. Hold dose increase. Reassess in 2 weeks.
Severe
Hold GLP-1 until resolved. Check hydration/lytes. Resume at lower dose. If recurs, may be patient's max tolerated dose.
Vomiting
Mild
Ondansetron PRN. Liquid diet temporarily. Maintain hydration.
Moderate
Hold next GLP-1 dose. Anti-emetics. Check BMP for dehydration. Resume at lower dose.
Severe
ER evaluation if dehydrated. Hold GLP-1. IV fluids if needed. Restart at 2 dose levels lower when resolved.
Constipation
Mild
Increase water to 80+ oz. Add fiber supplement. Walking 30 min daily.
Moderate
MiraLAX 17g daily. Magnesium citrate. Stool softeners.
Severe
R/O obstruction with imaging. Stimulant laxative short-term. Consider dose reduction. GI referral if persistent.
Diarrhea
Mild
BRAT diet temporarily. Hydration with electrolytes. Usually self-limiting.
Moderate
Loperamide PRN. Check C. diff if antibiotic exposure. Monitor hydration.
Severe
Hold GLP-1. Stool studies. BMP. Evaluate for infectious etiology. Resume cautiously when resolved.
Red Flag Symptoms
Immediate Evaluation Required
Anti-Emetic Protocol
Clinical Disclaimer: For licensed healthcare providers. These algorithms are guidelines and do not replace clinical judgment. Verify current prescribing information and adapt to individual patient presentation.
Frequently Asked Questions
When should nausea prompt dose reduction vs. supportive care?
Supportive care first for mild-moderate nausea (dietary modification, ondansetron PRN, ginger). Dose hold if nausea causes dehydration or persists beyond 2-3 weeks at current dose. Dose reduction if nausea recurs after hold. Discontinuation only if persistent at lowest effective dose with maximal supportive care.
What are red flag symptoms requiring immediate evaluation?
Severe abdominal pain radiating to back (pancreatitis), persistent vomiting with dehydration, signs of bowel obstruction, allergic/anaphylactic reactions, severe injection site reactions, unexplained thyroid nodule or neck mass, acute kidney injury signs, or gallbladder symptoms (RUQ pain with fever).
How should I manage GLP-1-related constipation?
First-line: increase water and fiber intake, encourage physical activity. Second-line: osmotic laxatives (MiraLAX 17g daily). Third-line: stimulant laxatives short-term. If refractory, evaluate for obstruction. Consider dose reduction. Fiber supplements and magnesium citrate are well-tolerated long-term options.
When is GLP-1 discontinuation appropriate for side effects?
Consider discontinuation for: suspected pancreatitis (hold permanently if confirmed), severe allergic reaction, intolerable GI symptoms despite maximal management and dose reduction, suspected bowel obstruction, or severe psychiatric adverse effects. Document clinical reasoning.
Trimi Clinical Support
Compounded semaglutide from $99/mo or tirzepatide from $125/mo with clinical oversight.
View Treatment OptionsMedical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).